Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity

Abstract

This retrospective study was conducted to investigate the predictive factors associated with metamorphopsia after reduced-fluence photodynamic therapy (RFPDT) in patients with central serous chorioretinopathy (CSC) with good baseline visual acuity. A total of 36 eyes of 36 consecutive patients with resolved CSC after RFPDT and best-corrected visual acuity (BCVA) better than 1.0 (logarithm of the minimal angle of resolution (logMAR) 0) at baseline were examined. Metamorphopsia was measured using M-CHARTS at 12 months after RFPDT. An average of the horizontal and vertical M-CHARTS scores was applied for defining the extent of metamorphopsia. The association between M-CHARTS score at 12 months after RFPDT and clinical parameters (age, sex, duration of symptoms, BCVA, and findings of optical coherence tomography (OCT)) was investigated at baseline or 12 months after RFPDT. The M-CHARTS score at 12 months correlated significantly with duration of symptoms (P = 0.005), baseline outer nuclear layer (ONL) thickness (P = 0.009), central foveal thickness (CFT) (P = 0.001) at 12 months, and ONL thickness (P = 0.001) at 12 months after RFPDT. In the multivariate analysis of baseline-related factors, thinner ONL thickness before RFPDT (P = 0.010) was significantly associated with large metamorphopsia at 12 months after RFPDT in CSC patients with good baseline BCVA. Baseline ONL thickness may be a useful predictive factor of metamorphopsia after RFPDT in CSC patients with good baseline BCVA.

Latest Development on Genetics of Common Retinal Diseases

“…In a Chinese cohort, none of the 7 SNPs examined in CFH were associated with 1-month outcomes after PDT in patients with CSCR 95. In contrast, in a Japanese cohort with a 12-month follow-up, the minor T allele of ARMS2 A69S was associated with poor response to PDT in patients with chronic CSCR 96…”

“…95 In contrast, in a Japanese cohort with a 12month follow-up, the minor T allele of ARMS2 A69S was associated with poor response to PDT in patients with chronic CSCR. 96 In nAMD, pharmacogenetic studies on PDT have been focused on the ARMS2-HTRA1 and CFH genes, with variable results. In a Japanese cohort of wet AMD, the bestcorrected visual acuity (BCVA) 1 year after PDT was significantly increased in patients with HTRA1 rs11200638 GG as compared with patients with GA or AA.…”

Metamorphopsia and Morphological Changes in the Macula after Scleral Buckling Surgery for Macula-Off Rhegmatogenous Retinal Detachment

“…At present, few studies have been published concerning the correlation between the duration of detachment and the severity of metamorphopsia in RRD [ 27 ]. Some studies reported that metamorphopsia correlated significantly with duration of symptoms in macular hole, central serous chorioretinopathy, and BRVO [ 17 , 28 , 29 ]. However, So et al found no correlation in ERM [ 30 ].…”

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization

“…Central serous chorioretinopathy (CSC) causes retinal detachment, typically involving the macula, caused by the accumulation of subretinal fluid (SRF) accumulation [ 1 ]. Although CSC typically resolves spontaneously within 3–6 months [ 2 ] treatment administration should be considered to ensure the preservation of the quality of vision when SRF accumulation persists beyond this period.…”